NO20022585L - Pyrrolidinacetamidderivat alene eller i kombinasjon for behandling av forstyrrelser i sentralnervesystemet - Google Patents

Pyrrolidinacetamidderivat alene eller i kombinasjon for behandling av forstyrrelser i sentralnervesystemet

Info

Publication number
NO20022585L
NO20022585L NO20022585A NO20022585A NO20022585L NO 20022585 L NO20022585 L NO 20022585L NO 20022585 A NO20022585 A NO 20022585A NO 20022585 A NO20022585 A NO 20022585A NO 20022585 L NO20022585 L NO 20022585L
Authority
NO
Norway
Prior art keywords
treatment
combination
nervous system
central nervous
system disorders
Prior art date
Application number
NO20022585A
Other languages
English (en)
Norwegian (no)
Other versions
NO20022585D0 (no
Inventor
Yves Lamberty
Alain Matagne
Henrik Klitgaard
Tony Waegemans
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of NO20022585D0 publication Critical patent/NO20022585D0/no
Publication of NO20022585L publication Critical patent/NO20022585L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
NO20022585A 1999-12-01 2002-05-31 Pyrrolidinacetamidderivat alene eller i kombinasjon for behandling av forstyrrelser i sentralnervesystemet NO20022585L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99124269 1999-12-01
EP99123803 1999-12-01
PCT/EP2000/011808 WO2001039779A1 (en) 1999-12-01 2000-11-27 A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders

Publications (2)

Publication Number Publication Date
NO20022585D0 NO20022585D0 (no) 2002-05-31
NO20022585L true NO20022585L (no) 2002-07-25

Family

ID=26153183

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022585A NO20022585L (no) 1999-12-01 2002-05-31 Pyrrolidinacetamidderivat alene eller i kombinasjon for behandling av forstyrrelser i sentralnervesystemet

Country Status (32)

Country Link
US (2) US6903130B1 (is)
EP (4) EP1600167A3 (is)
JP (2) JP4249415B2 (is)
KR (1) KR20030016205A (is)
CN (1) CN100525761C (is)
AR (1) AR026610A1 (is)
AT (1) ATE361751T1 (is)
AU (1) AU773418B2 (is)
BG (1) BG106708A (is)
BR (1) BR0015974A (is)
CA (2) CA2475026A1 (is)
CO (1) CO5261590A1 (is)
CZ (1) CZ20021904A3 (is)
DE (1) DE60034815T2 (is)
EE (1) EE200200274A (is)
ES (1) ES2287039T3 (is)
HK (1) HK1052647B (is)
HU (1) HUP0204023A3 (is)
IL (2) IL149530A0 (is)
IS (1) IS6377A (is)
MX (1) MXPA02005275A (is)
MY (1) MY127980A (is)
NO (1) NO20022585L (is)
NZ (1) NZ518901A (is)
PL (1) PL357472A1 (is)
RO (1) RO121085B1 (is)
RU (1) RU2261093C2 (is)
SA (1) SA01210655B1 (is)
SK (1) SK7492002A3 (is)
TW (1) TWI238062B (is)
WO (1) WO2001039779A1 (is)
YU (1) YU37602A (is)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6756379B2 (en) 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
US7166610B2 (en) * 2002-12-11 2007-01-23 Taro Pharmaceuticals U.S.A., Inc. Method of treating movement disorders using barbituric acid derivatives
US7683071B2 (en) 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US7608636B2 (en) 2000-12-28 2009-10-27 Hamilton Pharmaceuticals, Inc. Medicines for treatment and prevention of neurogenic pain
US20040116505A1 (en) * 2001-02-23 2004-06-17 Gregory Krauss Treatment of tics, tremors and related disorders
AU2002344820B2 (en) * 2001-06-20 2006-12-14 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
ATE353645T1 (de) * 2001-10-08 2007-03-15 Ucb Sa Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
WO2003094913A1 (en) * 2002-05-14 2003-11-20 Ucb, S.A. Use of 2-oxo-1-pyrrolidone derivatives for the preparation of a drug
WO2004051222A2 (en) * 2002-12-03 2004-06-17 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
TR200503397T1 (tr) * 2003-03-18 2007-03-21 Hetero Drugs Limited Levetirasetam'ın yeni kristal formları.
GB0307860D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Organic compounds
US20070037882A1 (en) * 2003-04-22 2007-02-15 Astellas Pharma Inc. Remedy for cerebral neurodegenerative diseases using ppar agonist
WO2005032535A1 (ja) 2003-10-03 2005-04-14 Ono Pharmaceutical Co., Ltd. 神経再生促進剤
AU2006228947A1 (en) * 2005-03-30 2006-10-05 Mylan Pharmaceuticals Ulc Combined-step process for pharmaceutical compositions
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
WO2006127300A1 (en) * 2005-05-24 2006-11-30 Cambrex Charles City, Inc. SYNTHESIS OF (S)-α-ETHYL-2-OXO-1-PYRROLIDINEACETAMIDE
DK1909764T3 (da) 2005-07-26 2014-12-15 Ucb Pharma Sa Farmaceutisk sammensætninger omfattende levetiracetam og fremgangsmåde til deres fremstilling
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
FR2890563B1 (fr) * 2005-09-09 2007-10-19 Servier Lab Nouvelle association entre l'agomelatine et un agent thymoregulateur et les compositions pharmaceutiques qui la contiennent
ATE413875T1 (de) * 2006-01-24 2008-11-15 Teva Pharma Zusammensetzungen enthaltend levetiracetam und verfahren zu deren herstellung.
WO2007144195A2 (en) 2006-06-15 2007-12-21 Schwarz Pharma Ag Pharmaceutical composition with synergistic anticonvulsant effect
EP2051735B1 (en) * 2006-07-17 2012-08-29 Ramot, at Tel Aviv University Ltd. Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use treating pain and other cns disorders
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
AU2007346591A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of ADHD
AU2012201853B2 (en) * 2007-04-16 2013-06-27 Neurotune Ag Use of dimiracetam in the treatment of chronic pain
ITMI20070770A1 (it) * 2007-04-16 2008-10-17 Brane Discovery S R L Impiego di dimiracetam nel trattamento del dolore cronico
WO2009101616A1 (en) 2008-02-11 2009-08-20 Ramot At Tel Aviv University Ltd. Novel conjugates for treating neurodegenerative diseases and disorders
EP2331088A4 (en) * 2008-08-06 2011-10-12 Gosforth Ct Holdings Pty Ltd COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES
JP5917148B2 (ja) 2008-10-16 2016-05-11 ザ ジョーンズ ホプキンズ ユニバーシティＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ 認知機能を改善するための方法および組成物
PL389364A1 (pl) * 2009-10-23 2011-04-26 Uniwersytet Jagielloński Nowe zastosowanie pochodnych 2-pirolidonu
JP2013520488A (ja) 2010-02-24 2013-06-06 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド ペルフェナジン−ｇａｂａのトリメシラート塩の結晶性形態物及びその製法方法
WO2011126733A2 (en) * 2010-03-28 2011-10-13 Children's Medical Center Corporation Combination therapies: inhibitors of gaba transaminase and nkcc1
WO2012038963A1 (en) 2010-09-22 2012-03-29 Ramot At Tel-Aviv University Ltd. An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
AU2018208662B2 (en) * 2012-11-14 2020-07-23 The Johns Hopkins University Methods and Compositions for Treating Schizophrenia
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
US11160785B2 (en) 2013-03-15 2021-11-02 Agenebio Inc. Methods and compositions for improving cognitive function
KR101690175B1 (ko) * 2013-07-02 2016-12-27 경희대학교 산학협력단 고본 추출물을 유효성분으로 포함하는 불면증의 예방 또는 치료용 약학적 조성물
RU2538724C1 (ru) * 2013-12-19 2015-01-10 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Способ лечения эпилепсии
KR20220038826A (ko) * 2014-01-21 2022-03-29 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
KR20200036063A (ko) 2014-01-21 2020-04-06 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
RU2563124C1 (ru) * 2014-04-28 2015-09-20 Федеральное государственное бюджетное учреждение "Федеральный медицинский исследовательский центр психиатрии и наркологии имени В.П. Сербского" Министерства здравоохранения Российской Федерации (ФГБУ "ФМИЦПН им. В.П. Сербского" Минздрава России) Способ диагностики шизофрении
MX384391B (es) 2015-05-22 2025-03-14 Agenebio Inc Composiciones farmacéuticas de levetiracetam de liberación extendida.
AU2017341927B2 (en) * 2016-10-14 2021-12-16 CNS Biosciences, Inc. Treating neuropathic pain in spinal cord injured individuals
PL244071B1 (pl) * 2019-01-07 2023-11-27 Univ Jagiellonski Pochodne (2,5-dioksopirolidyn-1-ylo)(fenylo)-acetamidu i ich zastosowanie do leczenia chorób o podłożu neurologicznym

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8412357D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
GB8827389D0 (en) 1988-11-23 1988-12-29 Ucb Sa Process for preparation of(s)alpha-ethyl-2-oxo-1-pyrrolidineacetamide
EP0408782A1 (en) 1989-07-18 1991-01-23 Nauchnoissledovatelski Chimikopharmatzevtichen Institut Antihypoxic agent
GB9319732D0 (en) 1993-09-24 1993-11-10 Ucb Sa Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
US5998380A (en) * 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine
JP2002508362A (ja) 1997-12-16 2002-03-19 ワーナー−ランバート・カンパニー １−置換−１−アミノメチル−シクロアルカン誘導体（＝ガバペンチン類縁体）、その製造および神経学的疾患の治療におけるその使用
CA2309354A1 (en) 1998-01-23 1999-07-29 Leslie Magnus-Miller Gabapentin and its derivatives for the treatment of muscular and skeletal pain
DE19820381B4 (de) * 1998-05-07 2007-01-25 Trw Fahrwerksysteme Gmbh & Co Kg Verfahren zur Beeinflussung der Ventilkennlinie
AU2384500A (en) * 1998-12-23 2000-07-12 Cytoscan Sciences L.L.C. Compounds, methods of screening and methods of treatment for central and peripheral nervous system disorders
US6495601B1 (en) 1998-12-23 2002-12-17 Cytoscan Sciences Llc Methods and compositions for treating conditions of the central and peripheral nervous systems using non-synaptic mechanisms
ATE319453T1 (de) * 1999-07-01 2006-03-15 Pharmacia & Upjohn Co Llc Reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen
AU2003225813A1 (en) * 2002-03-18 2003-10-08 Roger K. Cady Preemptive prophylaxis of migraine
US20040116506A1 (en) * 2002-06-20 2004-06-17 Krusz John Claude Use of levetiracetam for treating or preventing acute headaches
WO2004051222A2 (en) * 2002-12-03 2004-06-17 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases

Also Published As

Publication number Publication date
JP4249415B2 (ja) 2009-04-02
IS6377A (is) 2002-05-10
EP1600168A3 (en) 2009-09-23
AU773418B2 (en) 2004-05-27
US6903130B1 (en) 2005-06-07
WO2001039779A1 (en) 2001-06-07
HK1052647B (zh) 2010-05-20
HUP0204023A2 (hu) 2003-03-28
US20050187205A1 (en) 2005-08-25
EE200200274A (et) 2003-06-16
CN100525761C (zh) 2009-08-12
RO121085B1 (ro) 2006-12-29
YU37602A (sh) 2005-07-19
JP2003515564A (ja) 2003-05-07
IL149530A (en) 2007-07-04
EP1244456A1 (en) 2002-10-02
HUP0204023A3 (en) 2005-03-29
RU2002117279A (ru) 2004-02-27
RU2261093C2 (ru) 2005-09-27
KR20030016205A (ko) 2003-02-26
PL357472A1 (en) 2004-07-26
MXPA02005275A (es) 2003-02-17
ATE361751T1 (de) 2007-06-15
CO5261590A1 (es) 2003-03-31
DE60034815T2 (de) 2008-01-31
CA2392879A1 (en) 2001-06-07
CA2392879C (en) 2005-03-29
EP1600167A3 (en) 2009-09-30
CN1402637A (zh) 2003-03-12
DE60034815D1 (de) 2007-06-21
NZ518901A (en) 2004-08-27
CZ20021904A3 (cs) 2002-11-13
EP1600169A2 (en) 2005-11-30
EP1600168A2 (en) 2005-11-30
JP2008056697A (ja) 2008-03-13
TWI238062B (en) 2005-08-21
SK7492002A3 (en) 2003-02-04
EP1600169A3 (en) 2009-09-23
MY127980A (en) 2007-01-31
IL149530A0 (en) 2002-11-10
BG106708A (bg) 2003-02-28
CA2475026A1 (en) 2001-06-07
EP1244456B1 (en) 2007-05-09
ES2287039T3 (es) 2007-12-16
AU1524101A (en) 2001-06-12
AR026610A1 (es) 2003-02-19
EP1600167A2 (en) 2005-11-30
SA01210655B1 (ar) 2006-10-29
BR0015974A (pt) 2002-07-23
HK1052647A1 (zh) 2003-09-26
NO20022585D0 (no) 2002-05-31

Similar Documents

Publication Publication Date Title
NO20022585L (no) Pyrrolidinacetamidderivat alene eller i kombinasjon for behandling av forstyrrelser i sentralnervesystemet
NO20031903L (no) Nye amidoalkylpiperidin- og amidoalkylpiperazinderivater for anvendelse vedbehandling av nervesystemlidelser
NO20005884D0 (no) Kombinasjonsterapi for behandling av bipolare forstyrrelser
PT2266594E (pt) Vegf para utilização no tratamento de distúrbios do sistema nervoso central
DE69925571D1 (de) Sulphonamid-derivate zur behandlung von störungen des zentralnervensystems
AU9112201A (en) Pulmonary delivery in treating disorders of the central nervous system
EP1471909A4 (en) PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
NO20021845L (no) Behandling av sovnforstyrrelser under anvendelse av desloratadin
NO20043085L (no) Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet
PL350679A1 (en) Derivatives of 1-arenosulphonyl-2-arylpyrolydine and piperidine for treating central nervous system disorders
NO20032636D0 (no) 3-indolinderivater som er nyttige i behandlingen av psykiatriske og nevrologiske forstyrrelser
DK0908458T3 (da) Substituerede pyridylmethylpiperazin- og piperidinderivater, deres fremstilling samt deres anvendelse til behandling af lidelser i centralnervesystemet (CNS)
GB0015225D0 (en) Novel substituted nitrocatechols their use in the tratment of some central and peripheral nervous system disorders
IS6137A (is) Meðhöndlun á hugsýkistruflunum
NO20012106L (no) Middel for behandling av forstyrrelser i benmetabolismen
NO20015228L (no) Anvendelse av saredutant og de farmasöytisk aksepterbare salter derav for fremstilling av medikamenter anvendt for åbehandle eller forebygge sinnslidelser, tilpasningslidelser ellerblandede angst-depresjonslidelser
EE200000391A (et) Triasiiniühendid kesknärvisüsteemihäirete raviks
ID23175A (id) Penggunaan benzopiranol untuk mengobati gangguan syaraf
PT1152756E (pt) Derivados de anticonvulsivo uteis no tratamento do autismo
ATE287718T1 (de) Benzenesulfonamide derivate in kombination mit beta-blockern zur behandlung von störungen des autonomen nervensystems
DK0935598T3 (da) 5-heteroatom-alkylsubstituerede 3-oxopyrido(1,2-a)benzimidazol-4-carboxamidderivater egnede til behandling af sygdomme i centralnervesystemet
NO20023803L (no) Anvendelse av mirtazapin for behandling av sövnforstyrrelser
ATE374197T1 (de) Indolderivate zur behandlung von erkrankungen des zentralnervensystems
PL351554A1 (en) Osanetant in the treatment of mood disorders
IS2172B (is) Indól afleiður sem eru nytsamlegar fyrir meðhöndlun á taugakerfistruflunum

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application